Search

Displaying results 11 - 14 of 14 in total
  1. Indication

    Neovascular (Wet) Age-related Macular Degeneration (nAMD)

    go.drugbank.com/conditions/DBCOND0158368
    Drugs: Aflibercept · Bevacizumab · Brolucizumab · Faricimab · Pegaptanib · Ranibizumab
  2. Drug

    Faricimab

    go.drugbank.com/drugs/DB15303
    ApprovedInvestigational

    [A225985, A225990, A225995] Vascular endothelial growth factor A (VEGF-A) is a well-known mediator of retinal NV, and many currently approved RVD therapies such as [aflibercept] and [ranibizumab] solely

  3. Indication

    Metastatic Colorectal Cancer (CRC)

    go.drugbank.com/conditions/DBCOND0134580
    Drugs: Aflibercept · Bevacizumab · Cetuximab · Encorafenib · Fluorouracil · Fruquintinib +12 more
  4. Pathway

    Faricimab Action Pathway

    smpdb.ca/view/SMP0126914
    Drug action

    While existing treatments like aflibercept and ranibizumab focus solely on inhibiting VEGF-A, faricimab's unique mechanism involves binding to and depleting both VEGF-A and Ang-2.

    Drugs: Calcium · Faricimab